Boston Scientific Corporation (BSX)

Over the past six months, Boston Scientific's stock price has increased significantly. Strong Q1 CY2025 results, exceeding revenue expectations, led to management raising its full-year adjusted EPS guidance. FDA approvals for the FARAPULSE PFA System and label expansion for Watchman FLX devices contributed to strong demand. The acquisition of Axonics, Inc. is expected to bolster its Urology division. Analysts have reiterated "Buy" ratings, reflecting a bullish outlook. The decision to stop sales of Acurate Neo2 and Acurate Prime TAVR devices is expected to offset some positive impacts from lower tariffs.

Boston Scientific's net sales are influenced by general economic conditions and the capacity of healthcare systems. Improved hospital staffing constraints in 2023 allowed more patients to be treated, positively impacting sales. The company has reported strong and continued demand for key products like Farapulse and Watchman, and anticipates robust growth in its Urology and Cardiovascular divisions. Financial performance has also been affected by the offloading of surplus COVID inventories in 2023 and 2024, which acted as a headwind for overall demand.

Boston Scientific Corporation is a global medical technology company focused on developing, manufacturing, and marketing less-invasive medical devices. The company operates in the Health Technology sector, specifically the Medical Device industry, and is divided into two segments: MedSurg and Cardiovascular. The company provides innovative medical solutions that help physicians improve patient quality of life by offering alternatives to surgery. Key areas of focus include Cardiovascular, Cardiac Rhythm Management, Electrophysiology, Peripheral Interventions, Endoscopy, Urology and Women's Health, and Neuromodulation.

Boston Scientific's corporate headquarters are located in Marlborough, Massachusetts, U.S., with regional headquarters in Europe (France) and Asia Pacific (Singapore), and a U.S. Government Affairs office in Washington, D.C. The company operates in over 100 countries and has approximately 53,000 employees worldwide. Manufacturing facilities are situated in the U.S., Ireland, Costa Rica, Brazil, Malaysia, and Puerto Rico. Boston Scientific sells its products directly and through a network of distributors and dealers across Europe, the Middle East, Africa, Asia Pacific, and the Americas, with foreign sales accounting for nearly half of the company's total sales.

Boston Scientific maintains a strong brand reputation, built on its commitment to quality, ethical business practices, environmental sustainability, and community engagement. However, the company has faced events that could impact its reputation. Pacemaker advisories were issued in December 2023 and December 2024 (updated February 2025) regarding potential battery issues leading to devices entering "Safety Mode," with reported pauses and deaths, highlighting potential safety concerns and the need for early device replacement in affected devices.

Boston Scientific is primarily owned by institutional shareholders, who hold approximately 88.93% of the company's stock. Insiders own about 5.72%, and retail investors hold 5.35%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Fmr Llc, State Street Corp, Primecap Management Co/ca/, Wellington Management Group Llp, Geode Capital Management, Llc, and Bank Of America Corp /de/. Promerica LP is noted as the largest individual Boston Scientific shareholder.